Paper36969889
96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients.
Liu Z and 26 others. J Clin Transl Hepatol, 2023. Cited by 46 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. 96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients. Papers, record 36969889. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36969889
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- 96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03903796 | Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection | Derived from the trial | Yes |
Source ClinicalTrials.gov
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31,400,968 | Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics. | J Clin Densitom | 2019 | https://conductscience.org/library/papers/31400968 | PubMed |
| 2 | 18,260,800 | Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. | AIDS Patient Care STDS | 2008 | https://conductscience.org/library/papers/18260800 | PubMed |
| 3 | 31,237,366 | An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory-Wide Study From 2000 to 2017. | Hepatology | 2020 | https://conductscience.org/library/papers/31237366 | PubMed |
| 4 | 28,792,763 | The ProTide Prodrug Technology: From the Concept to the Clinic. | J Med Chem | 2018 | https://conductscience.org/library/papers/28792763 | PubMed |
| 5 | 25,948,863 | Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. | J Infect Dis | 2015 | https://conductscience.org/library/papers/25948863 | PubMed |
| 6 | 25,525,197 | Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. | J Antimicrob Chemother | 2015 | https://conductscience.org/library/papers/25525197 | PubMed |
| 7 | 31,606,734 | Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. | Clin Infect Dis | 2020 | https://conductscience.org/library/papers/31606734 | PubMed |
| 8 | 36,105,197 | Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36105197 | PubMed |
| 9 | 25,870,325 | The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. | Clin Infect Dis | 2015 | https://conductscience.org/library/papers/25870325 | PubMed |
| 10 | 19,414,839 | A new equation to estimate glomerular filtration rate. | Ann Intern Med | 2009 | https://conductscience.org/library/papers/19414839 | PubMed |
| 11 | 20,495,438 | A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. | AIDS | 2010 | https://conductscience.org/library/papers/20495438 | PubMed |
| 12 | 17,983,800 | Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. | Gastroenterology | 2007 | https://conductscience.org/library/papers/17983800 | PubMed |
| 13 | 12,460,055 | Fanconi syndrome and renal failure induced by tenofovir: a first case report. | Am J Kidney Dis | 2002 | https://conductscience.org/library/papers/12460055 | PubMed |
| 14 | 32,522,576 | Performance of Indexed and Nonindexed Estimated GFR. | Am J Kidney Dis | 2020 | https://conductscience.org/library/papers/32522576 | PubMed |
| 15 | 27,283,043 | Effects of nucleos(t)ide analogs on body composition in HBV-infected men: An age- and BMI-matched, cross-sectional study. | Nutrition | 2016 | https://conductscience.org/library/papers/27283043 | PubMed |
| 16 | 20,648,555 | A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. | Hepatology | 2010 | https://conductscience.org/library/papers/20648555 | PubMed |
| 17 | 27,575,311 | The role of quantitative hepatitis B surface antigen revisited. | J Hepatol | 2017 | https://conductscience.org/library/papers/27575311 | PubMed |
| 18 | 9,242,686 | Parathyroid hormone-dependent degradation of type II Na+/Pi cotransporters. | J Biol Chem | 1997 | https://conductscience.org/library/papers/9242686 | PubMed |
| 19 | 23,234,725 | Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. | Lancet | 2013 | https://conductscience.org/library/papers/23234725 | PubMed |
| 20 | 22,506,503 | Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. | Aliment Pharmacol Ther | 2012 | https://conductscience.org/library/papers/22506503 | PubMed |
Cited by39
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 46 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,802,125 | [Effect of switching from entecavir to tenofovir amibufenamide on HBsAg levels in patients with chronic hepatitis B: a 96-week real-world study]. | Zhonghua Gan Zang Bing Za Zhi | 2026 | https://conductscience.org/library/papers/42802125 | PubMed |
| 42,802,121 | [Expert recommendations on the first-line use and optimization plan of nucleos(t)ide analogues in the context of functional cure for chronic hepatitis B]. | Zhonghua Gan Zang Bing Za Zhi | 2026 | https://conductscience.org/library/papers/42802121 | PubMed |
| 42,750,716 | Real-world effectiveness and safety of tenofovir amibufenamide in treatment-naïve chronic hepatitis B: a 48-week retrospective cohort study. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42750716 | PubMed |
| 42,707,612 | Pradefovir mesylate and tenofovir amibufenamide for chronic hepatitis B: a systematic review and pragmatic treatment algorithm. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42707612 | PubMed |
| 42,106,615 | Effectiveness and safety of tenofovir amibufenamide in the treatment of chronic hepatitis B patients with low-level viremia: a retrospective real-world study. | BMC Gastroenterol | 2026 | https://conductscience.org/library/papers/42106615 | PubMed |
| 41,945,711 | A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B. | Hepatology | 2026 | https://conductscience.org/library/papers/41945711 | PubMed |
| 41,828,677 | Accuracy of Diagnostic Investigations in Monitoring Hepatitis B Virus Infection: Strengths, Limitations, and Emerging Biomarkers. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41828677 | PubMed |
| 41,312,460 | Effectiveness and safety of tenofovir alafenamide in chronic hepatitis B patients over 30 years old with positive hepatitis B virus DNA: a double-center retrospective study. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/41312460 | PubMed |
| 41,136,921 | Efficacy of TDF, TAF, TMF, and TDF-to-TAF switch in chronic hepatitis B: a network meta-analysis. | BMC Gastroenterol | 2025 | https://conductscience.org/library/papers/41136921 | PubMed |
| 41,060,358 | A Real-World Pharmacological Assessment of Tenofovir Amibufenamide and Tenofovir Alafenamide in 48-Week Chronic Hepatitis B Treatment: Efficacy, Safety, and Cost-Effectiveness. | Curr Med Sci | 2025 | https://conductscience.org/library/papers/41060358 | PubMed |
| 40,937,079 | Interim Analysis of 48-week Tenofovir Amibufenamide Treatment in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase Levels: The PROMOTE Study. | J Clin Transl Hepatol | 2025 | https://conductscience.org/library/papers/40937079 | PubMed |
| 40,821,631 | Serum TNF-a and biomarkers levels after tenofovir therapy in patients with serum HBeAg-positive chronic hepatitis B. | J Med Biochem | 2025 | https://conductscience.org/library/papers/40821631 | PubMed |
| 40,691,459 | Current landscape of innovative drug development and regulatory support in China. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/40691459 | PubMed |
| 40,678,712 | Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch. | World J Gastroenterol | 2025 | https://conductscience.org/library/papers/40678712 | PubMed |
| 40,390,028 | Recurrence risk factors for chronic hepatitis B virus-infected patients who achieve functional cure with pegylated interferon-α-2b-based therapy: a multicenter pilot study. | Virol J | 2025 | https://conductscience.org/library/papers/40390028 | PubMed |
| 40,248,094 | Effectiveness and safety of tenofovir amibufenamide and tenofovir alafenamide in treating elderly patients diagnosed with decompensated hepatitis B cirrhosis: a retrospective cohort study. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40248094 | PubMed |
| 40,093,664 | Tenofovir amibufenamide: A potential alternative for chronic hepatitis B treatment. | World J Gastroenterol | 2025 | https://conductscience.org/library/papers/40093664 | PubMed |
| 40,078,202 | Effectiveness and Safety of Tenofovir Amibufenamide in the Treatment of Chronic Hepatitis B: A Real-world, Multicenter Study. | J Clin Transl Hepatol | 2025 | https://conductscience.org/library/papers/40078202 | PubMed |
| 39,971,517 | [A case of chronic hepatitis B in the treatment of tenofovir amibufenamide]. | Zhonghua Gan Zang Bing Za Zhi | 2024 | https://conductscience.org/library/papers/39971517 | PubMed |
| 39,971,513 | [A case of complete viral suppression after switching to tenofovir amibufenamide treatment with chronic hepatitis B and concomitant impaired renal function]. | Zhonghua Gan Zang Bing Za Zhi | 2024 | https://conductscience.org/library/papers/39971513 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| FAS | 355 | PubTator's text mining | https://conductscience.org/library/genes/355 | NCBI Gene |
| GPT | 2,875 | PubTator's text mining | https://conductscience.org/library/genes/2875 | NCBI Gene |
| HBE1 | 3,046 | PubTator's text mining | https://conductscience.org/library/genes/3046 | NCBI Gene |
| PTH | 5,741 | PubTator's text mining | https://conductscience.org/library/genes/5741 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| TENOFOVIR DISOPROXIL FUMARATE | CHEMBL1486 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1486 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36969889
GET https://conductscience.org/api/papers/v1/36969889/authors?page=2